| Year |
Citation |
Score |
| 2023 |
Facchin C, Fraga-Timiraos AB, Schmitt J, Babaa N, Pannu N, Aliaga A, Larroque AL, Jean-Claude BJ. Molecular Analysis of the Superior Efficacy of a Dual Epidermal Growth Factor Receptor (EGFR)-DNA-Targeting Combi-Molecule in Comparison with Its Putative Prodrugs 6-Mono-Alkylamino- and 6,6-Dialkylaminoquinazoline in a Human Osteosarcoma Xenograft Model. Cells. 12. PMID 36980255 DOI: 10.3390/cells12060914 |
0.537 |
|
| 2021 |
Rao S, Thibault B, Peyrard L, Larroque-Lombard AL, Rupp M, Thauvin C, Jean-Claude BJ. Quantitative Analysis of the Potency of Equimolar Two-Drug Combinations and Combi-Molecules Involving Kinase Inhibitors In Vitro: The Concept of Balanced Targeting. International Journal of Molecular Sciences. 22. PMID 34502481 DOI: 10.3390/ijms22179569 |
0.364 |
|
| 2020 |
Golabi N, Larroque AL, Peyrard L, Williams C, Jean-Claude BJ. Subcellular distribution and mechanism of action of AL906, a novel and potent EGFR inhibitor rationally designed to be green fluorescent. Investigational New Drugs. PMID 32648119 DOI: 10.1007/s10637-020-00958-7 |
0.475 |
|
| 2020 |
Schmitt J, Huang S, Goodfellow E, Williams C, Jean-Claude BJ. Design and Synthesis of a Trifunctional Molecular System "Programmed" to Block Epidermal Growth Factor Receptor Tyrosine Kinase, Induce High Levels of DNA Damage, and Inhibit the DNA Repair Enzyme (Poly(ADP-ribose) Polymerase) in Prostate Cancer Cells. Journal of Medicinal Chemistry. PMID 32484346 DOI: 10.1021/acs.jmedchem.9b02008 |
0.544 |
|
| 2020 |
Schmitt J, Goodfellow E, Huang S, Williams C, Gomes INF, Rosa MN, Reis RM, Yang R, Titi HM, Jean-Claude BJ. Comparative analysis of the dual EGFR-DNA targeting and growth inhibitory properties of 6-mono-alkylamino- and 6,6-dialkylaminoquinazoline-based type II combi-molecules. European Journal of Medicinal Chemistry. 192: 112185. PMID 32145644 DOI: 10.1016/J.Ejmech.2020.112185 |
0.507 |
|
| 2019 |
Gamero-Estevez E, Andonian S, Jean-Claude B, Gupta I, Ryan AK. Temporal Effects of Quercetin on Tight Junction Barrier Properties and Claudin Expression and Localization in MDCK II Cells. International Journal of Molecular Sciences. 20. PMID 31581662 DOI: 10.3390/Ijms20194889 |
0.305 |
|
| 2019 |
Sharifi Z, Abdulkarim B, Meehan B, Rak J, Daniel P, Schmitt J, Lauzon N, Eppert K, Duncan HM, Petrecca K, Guiot MC, Jean-Claude BJ, Sabri S. Antitumor Activity of a Binary EGFR/DNA Targeting Strategy Overcomes Resistance of Glioblastoma Stem cells to Temozolomide. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31540977 DOI: 10.1158/1078-0432.Ccr-19-0955 |
0.536 |
|
| 2019 |
Jusu S, Presley J, Jean-Claude B, Stochaj U, Kremer R. Abstract LB-024: Inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1): evidence for impaired vitamin D signaling in an MMTV-PYMT mouse model of breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-024 |
0.303 |
|
| 2019 |
Raveendrakumar R, Abdulkarim B, Bagchi M, Daniel P, Deri A, Jean-Claude B, Sabri S. EXTH-50. THIOREDOXIN REDUCTASE1 AND MGMT SYNTHETIC LETHALITY ENHANCES CYTOTOXICITY OF PRIMA-1MET(APR-246) AND AURANOFIN IN GLIOBLASTOMA Neuro-Oncology. 21: vi93-vi93. DOI: 10.1093/Neuonc/Noz175.381 |
0.493 |
|
| 2018 |
Rupp M, Mouhri ZS, Williams C, Jean-Claude BJ. Molecular analysis of the dual targeting of the epidermal growth factor receptor and the O-methylguanine-DNA methyltransferase with a double arm hybrid molecule. Oncotarget. 9: 35041-35055. PMID 30416678 DOI: 10.18632/oncotarget.25120 |
0.566 |
|
| 2018 |
Sharifi Z, Meehan B, Daniel P, Eppert K, Jean-Claude B, Rak J, Abdulkarim B, Sabri S. Pharmacokinetics of ZR2002, a combi-molecule with EGFR and DNA-damaging properties and its efficacy in an orthotopic glioblastoma mouse model Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy047.007 |
0.542 |
|
| 2018 |
Daniel P, Meehan B, Sabri S, Chaddad A, Jean-Claude B, Shenouda G, Rak J, Abdulkarim BS. Exploiting Molecular Subtype Cell Plasticity As Novel Strategy for Targeting Glioma Stem Cells Through Alternating Therapy International Journal of Radiation Oncology Biology Physics. 102. DOI: 10.1016/J.Ijrobp.2018.07.743 |
0.347 |
|
| 2017 |
Jusu S, Presley JF, Williams C, Das SK, Jean-Claude B, Kremer R. Examination of VDR/RXR/DRIP205 Interaction, Intranuclear Localization and DNA Binding in Ras-transformed Keratinocytes and Its Implication for Designing Optimal Vitamin D Therapy in Cancer. Endocrinology. PMID 29300860 DOI: 10.1210/En.2017-03098 |
0.378 |
|
| 2017 |
Senhaji Mouhri Z, Goodfellow E, Jean-Claude B. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells. Bmc Cancer. 17: 540. PMID 28800752 DOI: 10.1186/S12885-017-3504-1 |
0.535 |
|
| 2017 |
Thibault B, Jean-Claude B. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells. Journal of Ovarian Research. 10: 31. PMID 28446239 DOI: 10.1186/S13048-017-0319-2 |
0.413 |
|
| 2016 |
Goodfellow E, Senhaji Mouhri Z, Williams C, Jean-Claude BJ. Design, synthesis and biological activity of novel molecules designed to target PARP and DNA. Bioorganic & Medicinal Chemistry Letters. PMID 28003142 DOI: 10.1016/j.bmcl.2016.09.054 |
0.485 |
|
| 2016 |
Patyka M, Sharifi Z, Petrecca K, Mansure J, Jean-Claude B, Sabri S. Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status. Oncotarget. PMID 27533246 DOI: 10.18632/Oncotarget.11197 |
0.377 |
|
| 2015 |
Tedeschi AL, Eslami Z, Garoufalis E, Saleh RR, Omeroglu A, Altinel G, Ait-Tihyaty M, Jean-Claude B, Mihalcioiu C. Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysis. Oncotargets and Therapy. 8: 911-9. PMID 25960662 DOI: 10.2147/Ott.S71089 |
0.307 |
|
| 2015 |
Heravi M, Kumala S, Rachid Z, Jean-Claude BJ, Radzioch D, Muanza TM. ZRBA1, a Mixed EGFR/DNA Targeting Molecule, Potentiates Radiation Response Through Delayed DNA Damage Repair Process in a Triple Negative Breast Cancer Model. International Journal of Radiation Oncology, Biology, Physics. 92: 399-406. PMID 25823448 DOI: 10.1016/j.ijrobp.2015.01.026 |
0.52 |
|
| 2015 |
Rao S, Larroque-Lombard AL, Peyrard L, Thauvin C, Rachid Z, Williams C, Jean-Claude BJ. Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting. Plos One. 10: e0117215. PMID 25658745 DOI: 10.1371/Journal.Pone.0117215 |
0.398 |
|
| 2015 |
Huang Y, Rachid Z, Peyrard L, Senhaji Mouhri Z, Williams C, Jean-Claude BJ. Positional isomerization of a non-cleavable combi-molecule dramatically altered tumor cell response profile. Chemical Biology & Drug Design. 85: 153-62. PMID 25092264 DOI: 10.1111/cbdd.12402 |
0.559 |
|
| 2015 |
Mouhri ZS, Goodfellow E, Jean-Claude B. Abstract C185: Targeting PARP and DNA as a novel unimolecular combination model for the enhancement of chemosensitivity Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C185 |
0.551 |
|
| 2014 |
Amrein L, Larocque A, Davidson D, Peyrard L, Borrelli D, Jean-Claude B, Panasci L. Abstract 1881: New therapeutic options for CLL treatment: Src/c-abl-directed molecular re-engineering of chlorambucil and bendamustine Cancer Research. 74: 1881-1881. DOI: 10.1158/1538-7445.Am2014-1881 |
0.419 |
|
| 2013 |
Ait-Tihyaty M, Rachid Z, Larroque-Lombard AL, Jean-Claude BJ. ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity. Investigational New Drugs. 31: 1409-23. PMID 23959266 DOI: 10.1007/s10637-013-0008-y |
0.494 |
|
| 2013 |
Heravi M, Muanza T, Kumala S, Rachid Z, Jean-Claude B, Radzioch D. EGFR/DNA Targeting Molecule Potentiates Radiation Response in a Murine Breast Cancer Model International Journal of Radiation Oncology Biology Physics. 87. DOI: 10.1016/J.Ijrobp.2013.06.1719 |
0.465 |
|
| 2012 |
Larroque-Lombard AL, Ning N, Rao S, Lauwagie S, Halaoui R, Coudray L, Huang Y, Jean-Claude BJ. Biological effects of AL622, a molecule rationally designed to release an EGFR and a c-Src kinase inhibitor. Chemical Biology & Drug Design. 80: 981-91. PMID 22943437 DOI: 10.1111/Cbdd.12043 |
0.418 |
|
| 2012 |
Watt HL, Rachid Z, Jean-Claude BJ. The Concept of Divergent Targeting through the Activation and Inhibition of Receptors as a Novel Chemotherapeutic Strategy: Signaling Responses to Strong DNA-Reactive Combinatorial Mimicries. Journal of Signal Transduction. 2012: 282050. PMID 22523681 DOI: 10.1155/2012/282050 |
0.52 |
|
| 2012 |
Al-Safadi S, Domarkas J, Han Y, Brahimi F, Jean-Claude BJ. Enhancement of the cytotoxic potential of the mixed EGFR and DNA-targeting 'combi-molecule' ZRBA1 against human solid tumour cells by a bis-quinazoline-based drug design approach. Anti-Cancer Drugs. 23: 483-93. PMID 22421369 DOI: 10.1097/CAD.0b013e328351c101 |
0.594 |
|
| 2012 |
Fang Y, Qiu Q, Domarkas J, Larroque-Lombard AL, Rao S, Rachid Z, Gibbs BF, Gao X, Jean-Claude BJ. "Combi-targeting" mitozolomide: conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer. The Prostate. 72: 1273-85. PMID 22290742 DOI: 10.1002/Pros.22475 |
0.42 |
|
| 2012 |
Ait-Tihyaty M, Rachid Z, Mihalcioiu C, Jean-Claude BJ. Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda. Breast Cancer Research and Treatment. 133: 217-26. PMID 21915635 DOI: 10.1007/s10549-011-1756-z |
0.36 |
|
| 2012 |
Heravi M, Muanza T, Rachid Z, Jean-Claude B, Radzioch D. Combination of Ionizing Radiation and DNA/EGFR Binary Targeting Molecule Delays DNA Double-Strands Repair International Journal of Radiation Oncology Biology Physics. 84. DOI: 10.1016/J.Ijrobp.2012.07.1897 |
0.534 |
|
| 2012 |
Amaefuna SC, Harrington AM, Jean-Claude B, Nagar B, Henderson MN. Crystallization of the Abl Kinase Domain with Combi-Inhibitors, ZRF1 and ZRF2 Biophysical Journal. 102: 61a. DOI: 10.1016/J.Bpj.2011.11.364 |
0.433 |
|
| 2011 |
Golabi N, Brahimi F, Huang Y, Rachid Z, Qiu Q, Larroque-Lombard AL, Jean-Claude BJ. A bioanalytical investigation on the exquisitely strong in vitro potency of the EGFR-DNA targeting type II combi-molecule ZR2003 and its mitigated in vivo antitumour activity. Journal of Pharmaceutical and Biomedical Analysis. 56: 592-9. PMID 21764236 DOI: 10.1016/j.jpba.2011.06.013 |
0.457 |
|
| 2011 |
Golabi N, Rachid Z, Qiu Q, Huang Y, Jean-Claude BJ. In vitro and in vivo biodistribution of ZRS1, a stabilized type I N-acetoxymethyl carbamate-containing combi-molecule. Drug Metabolism Letters. 5: 141-9. PMID 21457144 DOI: 10.2174/187231211795305212 |
0.361 |
|
| 2011 |
Larroque-Lombard AL, Todorova M, Qiyu Q, Jean-Claude B. Synthesis and studies on three-compartment flavone-containing combi-molecules designed to target EGFR, DNA, and MEK. Chemical Biology & Drug Design. 77: 309-18. PMID 21294849 DOI: 10.1111/J.1747-0285.2011.01098.X |
0.561 |
|
| 2011 |
Huang Y, Rachid Z, Jean-Claude BJ. MGMT is a molecular determinant for potency of the DNA-EGFR-combi-molecule ZRS1. Molecular Cancer Research : McR. 9: 320-31. PMID 21263032 DOI: 10.1158/1541-7786.MCR-10-0407 |
0.598 |
|
| 2011 |
Banerjee R, Huang Y, Qiu Q, McNamee JP, Belinsky G, Jean-Claude BJ. The combi-targeting concept: mechanism of action of the pleiotropic combi-molecule RB24 and discovery of a novel cell signaling-based combination principle. Cellular Signalling. 23: 630-40. PMID 21138763 DOI: 10.1016/j.cellsig.2010.11.014 |
0.544 |
|
| 2011 |
MacPhee M, Rachid Z, Todorova M, Qiu Q, Belinsky G, Jean-Claude BJ. Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain. Investigational New Drugs. 29: 833-45. PMID 20428924 DOI: 10.1007/s10637-010-9431-5 |
0.536 |
|
| 2010 |
Todorova MI, Larroque AL, Dauphin-Pierre S, Fang YQ, Jean-Claude BJ. Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species. Molecular Cancer Therapeutics. 9: 869-82. PMID 20354119 DOI: 10.1158/1535-7163.MCT-09-0673 |
0.552 |
|
| 2010 |
Banerjee R, Huang Y, McNamee JP, Todorova M, Jean-Claude BJ. The combi-targeting concept: Selective targeting of the epidermal growth factor receptor- and Her2-expressing cancer cells by the complex combi-molecule RB24 Journal of Pharmacology and Experimental Therapeutics. 334: 9-20. PMID 20348204 DOI: 10.1124/jpet.109.160085 |
0.596 |
|
| 2010 |
Larroque-Lombard AL, Todorova M, Golabi N, Williams C, Jean-Claude BJ. Synthesis and uptake of fluorescence-labeled Combi-molecules by P-glycoprotein-proficient and -deficient uterine sarcoma cells MES-SA and MES-SA/DX5. Journal of Medicinal Chemistry. 53: 2104-13. PMID 20151639 DOI: 10.1021/jm9016043 |
0.393 |
|
| 2010 |
Tihyaty MA, Rachid Z, Jean-Claude B, Mihalcioiu C. Abstract A44: Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda® Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-A44 |
0.45 |
|
| 2009 |
Rachid Z, Macphee M, Williams C, Todorova M, Jean-Claude BJ. Design and synthesis of new stabilized combi-triazenes for targeting solid tumors expressing the epidermal growth factor receptor (EGFR) or its closest homologue HER2. Bioorganic & Medicinal Chemistry Letters. 19: 5505-9. PMID 19665377 DOI: 10.1016/j.bmcl.2009.05.060 |
0.379 |
|
| 2009 |
Heravi M, Rachid Z, Goudarzi A, Schlisser A, Jean-Claude BJ, Radzioch D, Muanza TM. Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule. Anti-Cancer Drugs. 20: 659-67. PMID 19581798 DOI: 10.1097/CAD.0b013e32832cb8bc |
0.449 |
|
| 2009 |
Qiu Q, Larroque AL, Gibbs B, Fang Y, Lakhrissi Y, Soucy JP, Mzengeza S, Rachid Z, Jean-Claude BJ. Molecular analysis of the in vivo metabolism and biodistribution of metabolically and non-metabolically activated combi-molecules of the triazene class. Drug Metabolism Letters. 3: 1-9. PMID 19356110 |
0.382 |
|
| 2009 |
Barchéchath S, Williams C, Saade K, Lauwagie S, Jean-Claude B. Rational design of multitargeted tyrosine kinase inhibitors: a novel approach. Chemical Biology & Drug Design. 73: 380-7. PMID 19291100 DOI: 10.1111/J.1747-0285.2009.00786.X |
0.532 |
|
| 2008 |
Katsoulas A, Rachid Z, McNamee JP, Williams C, Jean-Claude BJ. Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia. Molecular Cancer Therapeutics. 7: 1033-43. PMID 18483293 DOI: 10.1158/1535-7163.MCT-07-0179 |
0.4 |
|
| 2008 |
Larroque AL, Peori B, Williams C, Fang YQ, Qiu Q, Rachid Z, Jean-Claude BJ. Synthesis of water soluble bis-triazenoquinazolines: an unusual predicted mode of binding to the epidermal growth factor receptor tyrosine kinase. Chemical Biology & Drug Design. 71: 374-9. PMID 18324926 DOI: 10.1111/j.1747-0285.2008.00638.x |
0.378 |
|
| 2007 |
Rachid Z, Katsoulas A, Williams C, Larroque AL, McNamee J, Jean-Claude BJ. Optimization of novel combi-molecules: identification of balanced and mixed bcr-abl/DNA targeting properties. Bioorganic & Medicinal Chemistry Letters. 17: 4248-53. PMID 17572088 DOI: 10.1016/j.bmcl.2007.05.067 |
0.453 |
|
| 2007 |
Rachid Z, Brahimi F, Qiu Q, Williams C, Hartley JM, Hartley JA, Jean-Claude BJ. Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure-activity relationship. Journal of Medicinal Chemistry. 50: 2605-8. PMID 17472358 DOI: 10.1021/jm070144p |
0.539 |
|
| 2007 |
Amrein L, Loignon M, Goulet AC, Dunn M, Jean-Claude B, Aloyz R, Panasci L. Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair via inhibition of DNA-dependent protein kinase. The Journal of Pharmacology and Experimental Therapeutics. 321: 848-55. PMID 17351105 DOI: 10.1124/Jpet.106.118356 |
0.427 |
|
| 2007 |
Qiu Q, Domarkas J, Banerjee R, Merayo N, Brahimi F, McNamee JP, Gibbs BF, Jean-Claude BJ. The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 331-40. PMID 17200372 DOI: 10.1158/1078-0432.CCR-06-0812 |
0.527 |
|
| 2007 |
Qiu Q, Domarkas J, Banerjee R, Katsoulas A, McNamee JP, Jean-Claude BJ. Type II combi-molecules: design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05. Anti-Cancer Drugs. 18: 171-7. PMID 17159603 DOI: 10.1097/CAD.0b013e3280115fe8 |
0.54 |
|
| 2006 |
Domarkas J, Dudouit F, Williams C, Qiyu Q, Banerjee R, Brahimi F, Jean-Claude BJ. The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). Journal of Medicinal Chemistry. 49: 3544-52. PMID 16759097 DOI: 10.1021/jm0600390 |
0.497 |
|
| 2006 |
Merayo N, Rachid Z, Qiu Q, Brahimi F, Jean-Claude BJ. The combi-targeting concept: evidence for the formation of a novel inhibitor in vivo. Anti-Cancer Drugs. 17: 165-71. PMID 16428934 |
0.508 |
|
| 2005 |
Brahimi F, Rachid Z, McNamee JP, Alaoui-Jamali MA, Tari AM, Jean-Claude BJ. Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency. Biochemical Pharmacology. 70: 511-9. PMID 15982640 DOI: 10.1016/J.Bcp.2005.04.037 |
0.508 |
|
| 2005 |
Katsoulas A, Rachid Z, Brahimi F, McNamee J, Jean-Claude BJ. Engineering 3-alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcr-abl expressing leukemias. Leukemia Research. 29: 693-700. PMID 15863211 DOI: 10.1016/j.leukres.2004.11.012 |
0.467 |
|
| 2005 |
Katsoulas A, Rachid Z, Brahimi F, McNamee J, Jean-Claude BJ. Cytokinetics and mechanism of action of AKO4: a novel nitrogen mustard targeted to bcr-abl. Leukemia Research. 29: 565-72. PMID 15755509 DOI: 10.1016/j.leukres.2004.11.011 |
0.475 |
|
| 2005 |
Rachid Z, Brahimi F, Domarkas J, Jean-Claude BJ. Synthesis of half-mustard combi-molecules with fluorescence properties: correlation with EGFR status. Bioorganic & Medicinal Chemistry Letters. 15: 1135-8. PMID 15686928 DOI: 10.1016/j.bmcl.2004.12.015 |
0.409 |
|
| 2004 |
Matheson S, Qiu Q, Brahimi F, Dudouit F, Banerjee R, Rachid Z, Jean-Claude BJ. [Combi-molecules: a global approach towards better chemoselectivity and chemosensitivity]. Bulletin Du Cancer. 91: 911-5. PMID 15634632 |
0.759 |
|
| 2004 |
Brahimi F, Rachid Z, Qiu Q, McNamee JP, Li YJ, Tari AM, Jean-Claude BJ. Multiple mechanisms of action of ZR2002 in human breast cancer cells: a novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNA. International Journal of Cancer. 112: 484-91. PMID 15382076 DOI: 10.1002/ijc.20383 |
0.499 |
|
| 2004 |
Banerjee R, Rachid Z, Qiu Q, McNamee JP, Tari AM, Jean-Claude BJ. Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line. British Journal of Cancer. 91: 1066-73. PMID 15365562 DOI: 10.1038/sj.bjc.6602098 |
0.63 |
|
| 2004 |
Matheson SL, McNamee JP, Wang T, Alaoui-Jamali MA, Tari AM, Jean-Claude BJ. The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo. The Journal of Pharmacology and Experimental Therapeutics. 311: 1163-70. PMID 15358812 DOI: 10.1124/Jpet.104.071977 |
0.766 |
|
| 2004 |
Matheson SL, Brahimi F, Jean-Claude BJ. The combi-targetinG concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting "combi-triazene" SMA41. Biochemical Pharmacology. 67: 1131-8. PMID 15006549 DOI: 10.1016/J.Bcp.2003.10.035 |
0.745 |
|
| 2004 |
Qiu Q, Dudouit F, Banerjee R, McNamee JP, Jean-Claude BJ. Inhibition of cell signaling by the combi-nitrosourea FD137 in the androgen independent DU145 prostate cancer cell line. The Prostate. 59: 13-21. PMID 14991862 DOI: 10.1002/pros.10353 |
0.373 |
|
| 2003 |
Banerjee R, Rachid Z, McNamee J, Jean-Claude BJ. Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept. Journal of Medicinal Chemistry. 46: 5546-51. PMID 14640561 DOI: 10.1021/jm030423m |
0.561 |
|
| 2003 |
Rachid Z, Brahimi F, Katsoulas A, Teoh N, Jean-Claude BJ. The combi-targeting concept: chemical dissection of the dual targeting properties of a series of "combi-triazenes". Journal of Medicinal Chemistry. 46: 4313-21. PMID 13678409 DOI: 10.1021/jm030142e |
0.632 |
|
| 2003 |
Rachid Z, Katsoulas A, Brahimi F, Jean-Claude BJ. Synthesis of pyrimidinopyridine-triazene conjugates targeted to abl tyrosine kinase. Bioorganic & Medicinal Chemistry Letters. 13: 3297-300. PMID 12951113 |
0.306 |
|
| 2003 |
Matheson SL, McNamee JP, Jean-Claude BJ. Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41. Cancer Chemotherapy and Pharmacology. 51: 11-20. PMID 12497201 DOI: 10.1007/S00280-002-0525-4 |
0.766 |
|
| 2003 |
Qiu Q, Dudouit F, Matheson SL, Brahimi F, Banerjee R, McNamee JP, Jean-Claude BJ. The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties. Cancer Chemotherapy and Pharmacology. 51: 1-10. PMID 12497200 DOI: 10.1007/S00280-002-0524-5 |
0.763 |
|
| 2002 |
Brahimi F, Matheson SL, Dudouit F, McNamee JP, Tari AM, Jean-Claude BJ. Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulates. The Journal of Pharmacology and Experimental Therapeutics. 303: 238-46. PMID 12235257 DOI: 10.1124/Jpet.102.039099 |
0.778 |
|
| 2001 |
Matheson SL, McNamee J, Jean-Claude BJ. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy. The Journal of Pharmacology and Experimental Therapeutics. 296: 832-40. PMID 11181914 |
0.777 |
|
| 1997 |
Jean-Claude BJ, Mustafa A, Cetateanu ND, Damian Z, De Marte J, Yen R, Vasilescu D, Chan TH, Leyland-Jones B. Design and mechanism of action of a novel cytotoxic 1,2,3-triazene-containing heterocycle, 3,5-dimethyl-pyrido-1,2,3,5-tetrazepin-4-one (PYRZ), in the human epithelial ovarian cancer cell line NIH:OVCAR-3 in vitro. British Journal of Cancer. 76: 467-73. PMID 9275023 DOI: 10.1038/bjc.1997.411 |
0.389 |
|
| Show low-probability matches. |